“This article highlights the continuous world focus on the Massachusetts’ biotechnology landscape, and how the Boston area’s concentrated talent continues to attract the interest of internationally based drug developers.” – Chris Tamburrini
Takeda, a pharmaceutical company with its headquarters in Japan, and locations in Cambridge, has potential plans to buy Shire, a biotechnology company based out of Ireland with the majority of its workforce located in Boston. With this purchase, Takeda would be securing a better grip on the array of biotech companies that are rapidly growing throughout Cambridge and Boston. Just the discussion of an offer started a buzz within the global pharmaceutical industry since there haven’t been many mega-mergers like this in years.
A deal this significant would greatly impact the biotech sector in Massachusetts. Shire is the second largest life sciences organization in the state, with Takeda following closely behind. Shire is currently in the process of combining their MA workforce in two different locations. This gives potential to either a consolidation amongst to two organization or an expansion depending on post-merger strategy. These companies are working on developing treatments for rare diseases and certain learning disorders. Combining their forces will likely expedite R&D efforts with the ultimate mission of uncovering additional therapies.